pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-190b |
Genomic Coordinates | chr1: 154193665 - 154193743 |
Description | Homo sapiens miR-190b stem-loop |
Comment | None |
RNA Secondary Structure | ![]() |
Associated Diseases | ![]() |
Mature miRNA Information | |
---|---|
Mature miRNA | hsa-miR-190b |
Sequence | 11| UGAUAUGUUUGAUAUUGGGUU |31 |
Evidence | Not_experimental |
Experiments | |
Putative Targets |
miRNA Expression profile | |
---|---|
miRNAs in Extracellular Vesicles |
|
Circulating MicroRNA Expression Profiling |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | PM20D2 | ||||||||||||||||||||
Synonyms | ACY1L2 | ||||||||||||||||||||
Description | peptidase M20 domain containing 2 | ||||||||||||||||||||
Transcript | NM_001010853 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on PM20D2 | |||||||||||||||||||||
3'UTR of PM20D2 (miRNA target sites are highlighted) |
>PM20D2|NM_001010853|3'UTR 1 AAGACTTAGGGGCCACTTATAAATCAAGAAGACGTGATGATTTTTTTCTTTTAATCTCTTTTAATGAAGGCATGCTTGTT 81 TTTTAATCTTAAAGGAGTAAAATTCTTTTTACCTGATAAGTGAGGACAGGGTGTGGAGAAAACATATTAATTACCTCATA 161 TCTAAAGTGAAAATTTTTGCAAATCCGTACTTGATAGGATTATGATATTACAGGAGCTGGTATGTGATGCCATTCTTTCT 241 TTTTTTTTACCCCGCAACCACTCACCTTCACAGTAGTGATACCATTTCTTAACCTGGAGGATACATGGCATCATTTTTAT 321 AAAATATGTTAGTAAACCTTTTTGTAAGCCTTAAATGTTATGTGTATTTTTAAAAGCTTAAGAGATTTCAAACCTTATAT 401 TCAGAATTGACACCCATGAGAGTGTTTTGTGGTATAGGGTGGTAAACTTGTTCTCTAATCGTATATTAATTCCTCTACCA 481 GATTGTATATTTGAAGCCAGTGTCTTTCCTTTTTTTGTTTTAAGATAGAGCCTCGCTCTGTTGCCCAGGCTGAAGTGTAG 561 TGGCACAATCTCGGCTCACTGCAACCTCTGCCTCCCAGGTTCAAGTGATTCTCCTGCCTCAGCCTACCAAGTAGCTGGGA 641 TTACAGGTGTGTGGCACCATGCCCAGCTAATTTTTGTATTTTTAGTAGAGACGGCATTTCACCATGTTGGCCAGGCTGGT 721 CTCGAACTCCTGACCTCAGGTGATGCACCTGCCTCGGCCTCCTAAAGTGCTGGGATTACAGGCATGAGCCACCGCACCCG 801 GCCTGCCAGTGTCTTTTTAATACACATGTGTGTTGGTATTTTTAAATTGTTACAGTATCTAGCATATTGCTTACTCTGAA 881 TATTCAGTACTTTTTGAATAAGCAAATATTGCTTCCTTGCTTGGAATCATCAGAGTTTAAAGTAGCTTCGTGGATGGACC 961 ATGATCCTAAGATGAGTTTTAATTTTGTGTTTACAGTCATCTCTTGTACAACGTGGAGAAGAAAAGATATACTTACTACT 1041 TTGCTTCAGGTACACATAAGAAAACCTCTTTTTTAAAAAAATTTTTATTTTTTTACATAATAGAGACAGGGGCTCGCTGT 1121 AGCTTCCAGGCTGGCCTCAAACTCCTGGGCTCAAGCAATCCTCCTGTCTTGGCCTCCCAAAGTGTTGGGATTTCAGGTAT 1201 GAGACACCACACCTGCCCATTTTTGTTTGGTTTTTTAATGGGCAGGTTCTTGCTCTCCCAGGCTGGAGTGCAGTGGTGTA 1281 ATCACAGCTCACTGCAGTCTCGAACTCCTGGACTCAAGCAGTCCTCCCACCTCAGCCTCCTAAAGCACTGGGATTACAGG 1361 CTTGAGGCACTGCACCTGGCCCTGACCATTTTTTAAAAAGGTTAGGCTTAGTGCAAAGTTTAAAATTATATGATTCTTAA 1441 AATACTGAATTAGTTTCTAAACTAAACTAGAGGTATAGGTGGACCTGCTTGAGGTATCTTTGTTTTTATGGAACATTTTT 1521 ATTACATGCCTTTATAATTTTTCATTGTTCACACCCTGTACTGAAACCTTTTTCTCAAATACCAACTCTTGGCTATGTTA 1601 AATTTGTAGACTTTAAAAGATGTTATCTAAATTAATGGTTTAAATATACAAATTGAAAATATTTTCTTTTTAGTGGCAAT 1681 TTTAAAAGCAGGCCTTAATATGGGACCTGCTTTTAAAGTAAAATATGTGGTACTATGAATTACTAAATTGCTATATACCA 1761 TGTAATAGTGAGTATAGCTAATATTTAGTATGCCTTTTAAAAATTTTGGACTGCTTTTCGGTTTTAACAAATTCTCCACA 1841 TGTGAACTACTCAAGAAATTTTCCCTTTTTAATTGCCTCTATAGCACTCATAAGAGCTAGGGCATTAGGATAAACTAGAA 1921 TATTTTATGTTTATGAATACTTGTATAAACTTAAAAGTGTTTTGATTTCCCACAATTTCCCAAAGGAATGTTTATTTATT 2001 AAGAGTTGTGTTGATAATTTAACTGTTACAATTTCAGCAGTTGAATTCAGTGAACACTGGTTGAGGAGTGCCTATTTCTA 2081 AGCACTGGGTGTAAGAAGAAAAGACACTTGCAAAGGAAGAGCTAAGATTAACATAATTTCTTTGGTTTTTCTATTGCTTG 2161 TTATTATTATGTAAAAACTGGGTGGCAGTTCACAAGGAAGATTGTTGTAACAGAAGAGTGACAACCAATAGTTTTTTGAT 2241 CATTAAATCAAATTTTGTAAACAGTGGCAGGAGCGTGGACTTAAAACAAGGCTTGCTTATTTGGTTTTGTCAAAGTTTTA 2321 CGAAAATATATGATATATATTTATACTAAAACTATATAATCCTTAGATTTAGGAAAGCAATCAGTTAATGTCTTTAGCAC 2401 ACTAAAGCAGTATTAAACACAGGTACAAGTTGGAAATTGTAGAAAACTGAAAGAAAACAAGACAAAATGTCTATGGTAGG 2481 GAATAAAAGAGTTTAAGATATTATGTAAAATTATGTGTATTTTCTTCTCTTTTACATAAATTGTTTGTGAAAAGTGTGCT 2561 CAACTTTTTTACAAGAGTGATATTAACTTGGATTTATTTTTCAATATAATTTGGAGACCCTTTGTTATCCAAATAAAATT 2641 GATGAGTTTCTGTGCCTGTAAAAAAAAAAAAAAAAAAAAGAAAAGAAAAGACACTGTTGCATGCCCCAGAAAGCTTGTGG 2721 TGGGTGGTAAGTTCTCACGAGATTTATTTATCTGAGCAACATTGGGACTGAGGGAACATCTGAAAGCTACCATCTTGAAA 2801 ATTTTTGAGGAAGTGTTTCTGAAATATTTAAAAATACTTAAGTCAGTCATTTTGAACAAAAGAAATTGATACAATAAGTT 2881 TTTTTTTTTAAGGATGATTGTCTAATTTTGTAATATGTTGTTTTTTAAAAACCTGTCTGATGGTGTTTTATACATTTCTA 2961 ACTTTTTACCTGAGTTATCTCTTTAGTCTTTTGGAAAATACCCTACACAATACTAACCTTTAAAACTATCAAATTTTTGT 3041 TATAAGATAAATGTTATCTTTGTACTAGATAGCAACCCTTTATAAGGTTGTAAGGTATAATAAACTGCTTATTTTTTTAC 3121 ATACTTCATATCAAGCATTTTGCAGTCCAATTATATAGTTGAGGATGGTGTATTTTGATATGTATGAAGTTAATATTTTC 3201 AAGTAAGCAATCAGTCTACTACCATCAGATTATAAGCTTTTTTGTAATAATAGGTACATAAAATGTGTATGAAAAATCTA 3281 CAATAAACATGTTTATCTGATAGCAAAAAAAAAA Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | HEK293 |
Location of target site | 3'UTR |
Tools used in this research | TargetScan , miRTarCLIP , Piranha |
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in GSM545216. RNA binding protein: AGO2. Condition:miR-124 transfection
... - Hafner M; Landthaler M; Burger L; Khorshid et al., 2010, Cell. |
Article |
- Hafner M; Landthaler M; Burger L; Khorshid et al. - Cell, 2010
RNA transcripts are subject to posttranscriptional gene regulation involving hundreds of RNA-binding proteins (RBPs) and microRNA-containing ribonucleoprotein complexes (miRNPs) expressed in a cell-type dependent fashion. We developed a cell-based crosslinking approach to determine at high resolution and transcriptome-wide the binding sites of cellular RBPs and miRNPs. The crosslinked sites are revealed by thymidine to cytidine transitions in the cDNAs prepared from immunopurified RNPs of 4-thiouridine-treated cells. We determined the binding sites and regulatory consequences for several intensely studied RBPs and miRNPs, including PUM2, QKI, IGF2BP1-3, AGO/EIF2C1-4 and TNRC6A-C. Our study revealed that these factors bind thousands of sites containing defined sequence motifs and have distinct preferences for exonic versus intronic or coding versus untranslated transcript regions. The precise mapping of binding sites across the transcriptome will be critical to the interpretation of the rapidly emerging data on genetic variation between individuals and how these variations contribute to complex genetic diseases.
LinkOut: [PMID: 20371350]
|
CLIP-seq Support 1 for dataset GSM545216 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | HEK293 / miR-124 transfection |
Location of target site | ENST00000275072.4 | 3UTR | CUUAUUUUUUUACAUACUUCAUAUC |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 20371350 / GSE21578 |
CLIP-seq Viewer | Link |
MiRNA-Target Expression Profile | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
60 hsa-miR-190b Target Genes:
Functional analysis:
ID![]() |
Target | Description | Validation methods |
![]() |
![]() |
|||||||
Strong evidence | Less strong evidence | |||||||||||
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
|||||
MIRT054581 | IGF1 | insulin like growth factor 1 | ![]() |
![]() |
![]() |
![]() |
4 | 1 | ||||
MIRT066966 | ATXN7L3B | ataxin 7 like 3B | ![]() |
![]() |
2 | 2 | ||||||
MIRT192449 | SPRED1 | sprouty related EVH1 domain containing 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT250414 | TNRC6A | trinucleotide repeat containing 6A | ![]() |
![]() |
2 | 2 | ||||||
MIRT306294 | KLHL24 | kelch like family member 24 | ![]() |
![]() |
2 | 2 | ||||||
MIRT355845 | SGMS2 | sphingomyelin synthase 2 | ![]() |
![]() |
2 | 4 | ||||||
MIRT437770 | MTMR6 | myotubularin related protein 6 | ![]() |
1 | 1 | |||||||
MIRT437771 | MTMR6 | myotubularin related protein 6 | ![]() |
1 | 1 | |||||||
MIRT437772 | Mtmr6 | myotubularin related protein 6 | ![]() |
1 | 1 | |||||||
MIRT444672 | CDKL2 | cyclin dependent kinase like 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT446389 | PCDHB11 | protocadherin beta 11 | ![]() |
![]() |
2 | 2 | ||||||
MIRT446634 | SDC3 | syndecan 3 | ![]() |
![]() |
2 | 2 | ||||||
MIRT449410 | TRIM5 | tripartite motif containing 5 | ![]() |
![]() |
2 | 2 | ||||||
MIRT449560 | GPC5 | glypican 5 | ![]() |
![]() |
2 | 2 | ||||||
MIRT469928 | PTPRJ | protein tyrosine phosphatase, receptor type J | ![]() |
![]() |
2 | 6 | ||||||
MIRT473736 | MAP3K9 | mitogen-activated protein kinase kinase kinase 9 | ![]() |
![]() |
2 | 2 | ||||||
MIRT474210 | LDHA | lactate dehydrogenase A | ![]() |
![]() |
2 | 2 | ||||||
MIRT474583 | KLF6 | Kruppel like factor 6 | ![]() |
![]() |
2 | 2 | ||||||
MIRT476732 | FOXN2 | forkhead box N2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT478455 | DAB2 | DAB2, clathrin adaptor protein | ![]() |
![]() |
2 | 2 | ||||||
MIRT495327 | ADAMTS8 | ADAM metallopeptidase with thrombospondin type 1 motif 8 | ![]() |
![]() |
2 | 4 | ||||||
MIRT498615 | MTRNR2L10 | MT-RNR2-like 10 | ![]() |
![]() |
2 | 12 | ||||||
MIRT501734 | OVOL1 | ovo like transcriptional repressor 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT501849 | MTRNR2L8 | MT-RNR2-like 8 | ![]() |
![]() |
2 | 14 | ||||||
MIRT504678 | CYGB | cytoglobin | ![]() |
![]() |
2 | 4 | ||||||
MIRT506517 | MSANTD4 | Myb/SANT DNA binding domain containing 4 with coiled-coils | ![]() |
![]() |
2 | 6 | ||||||
MIRT507984 | BCL2L13 | BCL2 like 13 | ![]() |
![]() |
2 | 4 | ||||||
MIRT508444 | ZNF608 | zinc finger protein 608 | ![]() |
![]() |
2 | 4 | ||||||
MIRT511366 | IL6ST | interleukin 6 signal transducer | ![]() |
![]() |
2 | 4 | ||||||
MIRT520515 | TRA2B | transformer 2 beta homolog | ![]() |
![]() |
2 | 2 | ||||||
MIRT524571 | CALML4 | calmodulin like 4 | ![]() |
![]() |
2 | 4 | ||||||
MIRT531896 | INVS | inversin | ![]() |
![]() |
2 | 4 | ||||||
MIRT533916 | TATDN2 | TatD DNase domain containing 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT537503 | FAM13B | family with sequence similarity 13 member B | ![]() |
![]() |
2 | 2 | ||||||
MIRT541689 | CCDC160 | coiled-coil domain containing 160 | ![]() |
![]() |
2 | 8 | ||||||
MIRT544419 | ZNF460 | zinc finger protein 460 | ![]() |
![]() |
2 | 4 | ||||||
MIRT544615 | CSDE1 | cold shock domain containing E1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT545076 | IL7R | interleukin 7 receptor | ![]() |
![]() |
2 | 2 | ||||||
MIRT545849 | ZNF264 | zinc finger protein 264 | ![]() |
![]() |
2 | 4 | ||||||
MIRT547436 | MED4 | mediator complex subunit 4 | ![]() |
![]() |
2 | 2 | ||||||
MIRT550157 | ZNF223 | zinc finger protein 223 | ![]() |
![]() |
2 | 4 | ||||||
MIRT553948 | STAMBP | STAM binding protein | ![]() |
![]() |
2 | 2 | ||||||
MIRT554395 | SERP1 | stress associated endoplasmic reticulum protein 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT555667 | PGAM4 | phosphoglycerate mutase family member 4 | ![]() |
![]() |
2 | 4 | ||||||
MIRT564193 | PM20D2 | peptidase M20 domain containing 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT566792 | MKL2 | MKL1/myocardin like 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT566843 | LRRC58 | leucine rich repeat containing 58 | ![]() |
![]() |
2 | 2 | ||||||
MIRT572516 | KIAA0232 | KIAA0232 | ![]() |
![]() |
2 | 2 | ||||||
MIRT607428 | NOTCH2NL | notch 2 N-terminal like | ![]() |
![]() |
2 | 10 | ||||||
MIRT627779 | RAB30 | RAB30, member RAS oncogene family | ![]() |
![]() |
2 | 2 | ||||||
MIRT635159 | ENO4 | enolase family member 4 | ![]() |
![]() |
2 | 2 | ||||||
MIRT642159 | ADCYAP1R1 | ADCYAP receptor type I | ![]() |
![]() |
![]() |
3 | 2 | |||||
MIRT646205 | DUSP10 | dual specificity phosphatase 10 | ![]() |
![]() |
2 | 2 | ||||||
MIRT657007 | KCNMB4 | potassium calcium-activated channel subfamily M regulatory beta subunit 4 | ![]() |
![]() |
2 | 2 | ||||||
MIRT665817 | TMEM161B | transmembrane protein 161B | ![]() |
![]() |
2 | 2 | ||||||
MIRT667488 | MAP3K2 | mitogen-activated protein kinase kinase kinase 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT707098 | ZNF850 | zinc finger protein 850 | ![]() |
![]() |
2 | 2 | ||||||
MIRT708719 | PTPLAD2 | 3-hydroxyacyl-CoA dehydratase 4 | ![]() |
1 | 1 | |||||||
MIRT735521 | HUS1 | HUS1 checkpoint clamp component | ![]() |
![]() |
![]() |
3 | 0 | |||||
MIRT736644 | AGPAT3 | 1-acylglycerol-3-phosphate O-acyltransferase 3 | ![]() |
![]() |
2 | 0 |
miRNA-Drug Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|